{"id":"NCT00092495","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)","officialTitle":"A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-12","primaryCompletion":"2004-09","completion":"2009-02","firstPosted":"2004-09-27","resultsPosted":"2010-03-08","lastUpdate":"2015-01-13"},"enrollment":3055,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Cervical Cancer","Genital Warts"],"interventions":[{"type":"BIOLOGICAL","name":"V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine","otherNames":["V501","Gardasil"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"},{"label":"4","type":"EXPERIMENTAL"}],"summary":"The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.","primaryOutcome":{"measure":"Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3","timeFrame":"Week 4 Postdose 3 (Month 7)","effectByArm":[{"arm":"Girls 10-15 Years","deltaMin":423,"sd":null},{"arm":"Boys 10-15 Years","deltaMin":428,"sd":null},{"arm":"Women 16-23 Years","deltaMin":320,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["17079588","18313445","18000825","17955433","19935017","19453788"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":496},"commonTop":["Injection site pain","Headache","Injection site swelling","Injection site erythema","Pyrexia"]}}